The Surgical Cure of Diabetes: Sir Frederick Banting’s Dream Realized 100 Years after Insulin Discovery
This activity has been archived and credit is no longer available.
In this presentation, Dr. Phillip Schauer discusses the recent developments in the surgical treatment of diabetes mellitus. He also shares a historical perspective of the medical and surgical treatment of diabetes, starting with the discovery of insulin by a surgeon, Sir Frederick Banting, in 1921.
This Michael E. DeBakey Department of Surgery Grand Rounds session took place on Wednesday, March 23, 2022 at 7:00 A.M.
Activity Information
This activity has been archived and credit is no longer available.
Needs Statement
General, plastic, thoracic, vascular, cardiothoracic, abdominal transplantation and surgical oncology physicians, residents, fellows and medical students need to be regularly updated on novel therapies, as well as advances in surgical care and clinical practices that will aid them in treating a variety of surgical procedures to increase the patient care experience and improve practice efficiency.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Review the history of surgery regarding to treating diabetes.
- Describe the outcomes of medical versus surgical treatment of type 2 diabetes.
- Recognize frequency of diabetes remission after surgery.
- Demonstrate a greater understanding of the history of insulin and how it was discovered 100 years ago by surgeon, Frederick Banting, MD.
- Discuss being inspired by research and discovery.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
Specialties
- Surgery
Interest Groups
- Hospital Medicine
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Term of Approval
March 1, 2022 through March 31, 2024. Original release date: March 1, 2022.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Phillip Schauer, M.D.
Professor of Metabolic Surgery
Pennington Biomedical Research Center of Louisiana State University
Disclosure:
- Employment (with a commercial interest): Pennington Biomedical Research Center
- Research Support: Ethicon; Medtronic/Covidienm; Pacira Biosciences
- Consultancy: BD Surgical or Becton; Dickinson and Company; Ethicon; GI Dynamics; Global Academy for Medical Education, LLC; Medtronic/Covidienm; Persona Nutrition/Vitaminpacks, Inc.; Keyron LTD; WL Gore and Associates, Inc.
- Honorarium Recipient: Ethicon; Medtronic/Covidienm
- Board Membership: BD Surgical or Becton; Dickinson and Company; GI Dynamics; Persona Nutrition/Vitaminpacks, Inc.
- Ownership Interests (stock, stock options, excluding diversified mutual funds): Physicians Review of Surgery, LLD; Reimbursement Pathways; SE Healthcare, LLC
Activity Director
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Michele Loor, M.D., FACS
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Todd Rosengart, M.D., F.A.C.S.
DeBakey-Bard Chair of Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: